Histological validation of iron-oxide and gadolinium based MRI contrast agents in experimental atherosclerosis: The do's and don't's

Atherosclerosis

Volumn 225, Issue 2, 2012, Pages 274-280

  den Adel, Brigit ^a   Bovens, Sandra M ^b,e   Boekhorst, Bernard te ^c   Strijkers, Gustav J ^d   Poelmann, Robert E ^a   van der Weerd, Louise ^a   Pasterkamp, Gerard ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^e ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Atherosclerosis; Contrast agent; Histology; MRI

Indexed keywords

CONTRAST MEDIUM; EUROPIUM; GADOLINIUM; IRON OXIDE; NANOPARTICLE; PARAFFIN; PENTETIC ACID; RHODAMINE; TETRAXETAN;

ANTIGEN ANTIBODY COMPLEX; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CRYOPRESERVATION; DRUG ACCUMULATION; FALSE POSITIVE RESULT; FLUORESCENCE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; STAINING; TISSUE SECTION; VALIDATION STUDY;

ANIMALS; ARTERIES; ATHEROSCLEROSIS; CONTRAST MEDIA; DEXTRANS; DISEASE MODELS, ANIMAL; FALSE POSITIVE REACTIONS; GADOLINIUM; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MOLECULAR IMAGING; NANOPARTICLES; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS;

EID: 84869489811     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.07.028     Document Type: Review

References (38)

1. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009 Dec 1, 54(23):2129-2138.
2. Davies M.J. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White lecture 1995. Circulation 1996 Oct 15, 94(8):2013-2020.
3. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002 Mar 5, 105(9):1135-1143.
4. Stary H.C., Chandler A.B., Dinsmore R.E., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American heart association. Circulation 1995 Sep 1, 92(5):1355-1374.
5. Corti R., Fuster V., Badimon J.J., Hutter R., Fayad Z.A. New understanding of atherosclerosis (clinically and experimentally) with evolving MRI technology in vivo. Ann N Y Acad Sci 2001 Dec, 947:181-195.
6. Matter C.M., Stuber M., Nahrendorf M. Imaging of the unstable plaque: how far have we got?. Eur Heart J 2009 Nov, 30(21):2566-2574.
7. Saraste A., Nekolla S.G., Schwaiger M. Cardiovascular molecular imaging: an overview. Cardiovasc Res 2009 Sep 1, 83(4):643-652.
8. Choudhury R.P., Aguinaldo J.G., Rong J.X., et al. Atherosclerotic lesions in genetically modified mice quantified in vivo by non-invasive high-resolution magnetic resonance microscopy. Atherosclerosis 2002 Jun, 162(2):315-321.
9. Te Boekhorst B.C., Cramer M.J., Pasterkamp G., van Echteld C.J., Doevendans P.A. Recent developments and new perspectives on imaging of atherosclerotic plaque: role of anatomical, cellular and molecular MRI part I and II. Int J Cardiovasc Imaging 2010 Apr, 26(4):433-445.
10. Elster A.D., Jackels S.C., Allen N.S., Marrache R.C. Dyke award. Europium-DTPA: a gadolinium analogue traceable by fluorescence microscopy. AJNR Am J Neuroradiol 1989 Nov, 10(6):1137-1144.
11. Zhang S., Zhu X., Chen Z., Cai C., Lin T., Zhong J. Improvement in the contrast of CEST MRI via intermolecular double quantum coherences. Phys Med Biol 2008 Jul 21, 53(14):N287-N296.
12. Frame E.M., Uzgiris E.E. Gadolinium determination in tissue samples by inductively coupled plasma mass spectrometry and inductively coupled plasma atomic emission spectrometry in evaluation of the action of magnetic resonance imaging contrast agents. Analyst 1998 Apr, 123(4):675-679.
13. van Bochove G.S., Paulis L.E., Segers D., et al. Contrast enhancement by differently sized paramagnetic MRI contrast agents in mice with two phenotypes of atherosclerotic plaque. Contrast Media Mol Imaging 2011 Jan, 6(1):35-45.
14. Mulder W.J., Strijkers G.J., van Tilborg G.A., Griffioen A.W., Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 2006 Feb, 19(1):142-164.
15. van Bochove G.S., Paulis L.E., Segers D., Mulder W.J., Krams R., Nicolay K., et al. Contrast enhancement by differently sized paramagnetic MRI contrast agents in mice with two phenotypes of atherosclerotic plaque. Contrast Media Mol Imaging 2011 Jan, 6(1):35-45.
16. Kuhlencordt P.J., Gyurko R., Han F., et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 2001 Jul 24, 104(4):448-454.
17. Te Boekhorst B.C., Bovens S.M., Hellings W.E., et al. Molecular MRI of murine atherosclerotic plaque targeting NGAL: a protein associated with unstable human plaque characteristics. Cardiovasc Res 2011 Feb 15, 89(3):680-688.
18. van Tilborg G.A., Mulder W.J., van der Schaft D.W., et al. Improved magnetic resonance molecular imaging of tumor angiogenesis by avidin-induced clearance of nonbound bimodal liposomes. Neoplasia 2008 Dec, 10(12):1459-1469.
19. Blackwell M.L., Farrar C.T., Fischl B., Rosen B.R. Target-specific contrast agents for magnetic resonance microscopy. Neuroimage 2009 Jun, 46(2):382-393.
20. Higuchi M., Iwata N., Matsuba Y., Sato K., Sasamoto K., Saido T.C. 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat Neurosci 2005 Apr, 8(4):527-533.
21. Schmitz S.A. Iron-oxide-enhanced MR imaging of inflammatory atherosclerotic lesions: overview of experimental and initial clinical results. Rofo 2003 Apr, 175(4):469-476.
22. Jaffer F.A., Libby P., Weissleder R. Molecular imaging of cardiovascular disease. Circulation 2007 Aug 28, 116(9):1052-1061.
23. Gilad A.A., Winnard P.T., van Zijl P.C., Bulte J.W. Developing MR reporter genes: promises and pitfalls. NMR Biomed 2007 May, 20(3):275-290.
24. Hadjantonakis A.K., Dickinson M.E., Fraser S.E., Papaioannou V.E. Technicolour transgenics: imaging tools for functional genomics in the mouse. Nat Rev Genet 2003 Aug, 4(8):613-625.
25. 19F chemical shift imaging of LacZ gene-reporter molecule 2-fluoro-4-nitrophenol-beta-D-galactopyranoside. Magn Reson Imaging 2006 Sep, 24(7):959-962.
26. Louie A.Y., Huber M.M., Ahrens E.T., et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000 Mar, 18(3):321-325.
27. Li Z., Qiao H., Lebherz C., et al. Creatine kinase, a magnetic resonance-detectable marker gene for quantification of liver-directed gene transfer. Hum Gene Ther 2005 Dec, 16(12):1429-1438.
28. Walter G., Barton E.R., Sweeney H.L. Noninvasive measurement of gene expression in skeletal muscle. Proc Natl Acad Sci U S A 2000 May 9, 97(10):5151-5155.
29. Moore A., Basilion J.P., Chiocca E.A., Weissleder R. Measuring transferrin receptor gene expression by NMR imaging. Biochim Biophys Acta 1998 Apr 24, 1402(3):239-249.
30. Moore A., Josephson L., Bhorade R.M., Basilion J.P., Weissleder R. Human transferrin receptor gene as a marker gene for MR imaging. Radiology 2001 Oct, 221(1):244-250.
31. Weissleder R., Simonova M., Bogdanova A., Bredow S., Enochs W.S., Bogdanov A. MR imaging and scintigraphy of gene expression through melanin induction. Radiology 1997 Aug, 204(2):425-429.
32. Cohen B., Dafni H., Meir G., Harmelin A., Neeman M. Ferritin as an endogenous MRI reporter for noninvasive imaging of gene expression in C6 glioma tumors. Neoplasia 2005 Feb, 7(2):109-117.
33. Cohen B., Ziv K., Plaks V., Harmelin A., Neeman M. Ferritin nanoparticles as magnetic resonance reporter gene. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009 Mar, 1(2):181-188.
34. Choi H.S., Frangioni J.V. Nanoparticles for biomedical imaging: fundamentals of clinical translation. Mol Imaging 2010 Dec, 9(6):291-310.
35. Pedersen M. Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 2007 May, 25(5):881-883.
36. Bongartz G. Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency?. MAGMA 2007 Apr, 20(2):57-62.
37. Maurer M., Heine O., Wolf M., Durmus T., Wagner M., Hamm B. Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients. Eur J Radiol 2012 May, 81(5):885-890.
38. Nanotechnology: small matter, many unknowns 2004, Swiss Re.